Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

JNJ suffers to some extent from what I refer to as "Leaky Equity Bucket Syndrome."

Johnson & Johnson: Any Share Price Dip Could Be A Buy Opportunity

The company has a steady business but a big liability hanging over its head.

3 Reasons to Buy Johnson & Johnson, and 1 Reason to Sell

Over the weekend, Johnson & Johnson (NYSE:JNJ) reached a major opioid litigation settlement that could have broader implications for the biopharmaceutical industry. What Happened?

JNJ's $260M Settlement Could Serve As Global Opioid Deal Template: Analyst

Johnson & Johnson is the largest and most diverse health care company in the world. Over 135 years, it has grown into a leader in consumer health, medical devices and pharma, including vaccines.

Johnson & Johnson Equals Consistent Profitability And Dividends

Johnson & Johnson (JNJ) is an exemplary blue chip investment, combining long term compounding potential with a superb credit strength. At its current price levels (~$165), an investment in JNJ provides good potential for double digit total return with little risk in the long term.

Johnson & Johnson: A Compounder With Better Credit Than The US Government

Whether the pharmaceutical giant jumped or was pushed, its New York deal is a significant sign of the way the wind is blowing

‘Johnson & Johnson helped fuel this fire' – now it's out of the opioids business

On Saturday, Johnson & Johnson (NYSE: JNJ) said it would end the manufacture and sale of opioids nationwide in a $230 million settlement with the New York state, Reuters reports.  J&J will not face the jury trial scheduled to begin on Tuesday on Long Island with this settlement.

Johnson & Johnson Reaches $230M Settlement With New York State To End Sale Of Opioids Nationwide

Johnson & Johnson has agreed to a $230 million settlement with New York state, resolving complaints from the state's attorney general over the pharmaceutical company's role in the opioid epidemic.

Johnson & Johnson settles New York opioid suit in $230 million deal

The settlement was reached just days before the case was set to go to trial, The Wall Street Journal reported.

Johnson & Johnson will stop selling opioids in the US as part of $230 million settlement in New York

It's the latest in a string of legal actions by state and local governments against pharmaceutical companies that sold opioid painkillers.

Johnson & Johnson Agrees To Pay $230 Million To Resolve N.Y. Opioid Lawsuit

Johnson & Johnson agreed to pay about $230 million to resolve claims it helped fuel an opioid crisis in New York, the state's attorney general said on Saturday.

J&J reaches $230 million opioid settlement with New York state

Johnson & Johnson has agreed to halt sales of opioids nationwide in a $230 million settlement with New York state.

Johnson & Johnson agrees to stop selling opioids nationwide in $230 million settlement with New York state

Amazon

Teladoc

Two promise major growth. One will fill your pockets with dividend payments.

Ignore Biogen: Here Are 3 Better Stocks

Bayer AG

J&J (JNJ) and its partner Bayer seek approval of Xarelto as a treatment and prevention for venous thromboembolism in pediatric patients.

J&J (JNJ)/Bayer Seek Nod for Xarelto for Blood Clots in Kids

Could this longstanding Dividend King have the least risky payout in the sector?

Does Johnson & Johnson Have the Safest Dividend in Healthcare?

Realty Income Corp

These top stocks could help your portfolio ride out the next market crash.

Got $2,500? 2 Unstoppable Dividend Stocks to Buy

Darden Restaurants

FedEx

NIKE

Equinix

GlaxoSmithKline

CarMax

Paychex

Companies speaking with investors this week include Nike, FedEx, Johnson & Johnson, GlaxoSmithKline, and Darden Restaurants. Plus, PMIs, durable goods orders, and personal income and consumption.

Nike, FedEx, Johnson & Johnson, Darden, and Other Stocks to Watch This Week

Is Johnson & Johnson Now a Has-Been in the COVID Vaccine Market?

AstraZeneca

Emergent BioSolutions also ruined at least 15 million doses of Johnson & Johnson's COVID-19 vaccine earlier this year.

The US is scrambling to send promised vaccines abroad after the same production plant that ruined millions of J&J vaccines also taints AstraZeneca shots

Johnson & Johnson (NYSE: JNJ) will miss its COVID-19 vaccine supply target to the European Union for the second quarter after millions of doses were found unfit for use, Reuters reported citing the E.U. Commission spokesman.

JNJ Unlikely To Meet Q2 COVID-19 Vaccine Supply Target To EU: Reuters

Caterpillar

The broad markets saw a somewhat mixed performance to start out the week. The S&P 500 and Dow Jones industrial average were up and down 0.2% and 0.3%, respectively.

Jim Cramer Has a Closer Look at Caterpillar, Johnson & Johnson and More

J&J (JNJ) gets authorization for two batches of COVID-19 vaccine doses manufactured at Baltimore facility but the FDA discards several others. Europe and Canada stop the rollout of some batches of the vaccine.

J&J (JNJ) Gets FDA Nod for 10M COVID Vaccines, Discards Many

Janssen Pharmaceutical, a unit of Johnson & Johnson (NYSE: JNJ), announced overall survival (OS) results from the Phase 3 MAIA study evaluating the Darzalex combo in patients with newly diagnosed multiple myeloma. After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed.

Johnson & Johnson Building Case With New Patient Survival Data For Darzalex In Multiple Myeloma

AbbVie

A combination of Johnson & Johnson's (NYSE: JNJ) Imbruvica and AbbVie Inc (NYSE: ABBV) - Roche Holding AG's (OTC: RHHBY) Venclexta/Venclyxto (venetoclax) slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche's Gazyva and the chemotherapy chlorambucil in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients. The phase 3 GLOW trial data were shared at the European Hematology Association (EHA) annual meeting.

JNJ's Imbruvica, AbbVie's Venclexta Combo Achieves Progression-Free Survival Of 78.4% Versus Gazyva-Chemo Cocktail In Leukemia Patients

Johnson & Johnson's Medical Devices Division is seeing double digit growth in core businesses thanks to the post-Pandemic recovery. Johnson & Johnson's continued success in Oncology is driving strong growth in the company's Pharmaceutical Division.

News for Johnson & Johnson Stock (JNJ)